ABEONA THERAPEUTICS INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ABEONA THERAPEUTICS INC. (ABEO) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $335.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- ABEONA THERAPEUTICS INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $335.00K, a 65.39% decline year-over-year.
- ABEONA THERAPEUTICS INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $105.00K.
- ABEONA THERAPEUTICS INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $222.00K.
- ABEONA THERAPEUTICS INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $1.42M.
- ABEONA THERAPEUTICS INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $419.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $335.00K 10-Q · filed 2026-08-13 | $440.00K derived: sum of 3 quarters · filed 2026-08-13 | $662.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $335.00K 10-Q · filed 2026-05-13 | $440.00K derived: sum of 2 quarters · filed 2026-05-13 | $662.00K derived: sum of 3 quarters · filed 2026-05-13 | $791.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $105.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $327.00K derived: sum of 2 quarters · filed 2026-03-17 | $456.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.42M 10-K · filed 2026-03-17 |
| 2025-09-30 | $222.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $351.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.32M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $129.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.10M 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | $968.00K 10-Q · filed 2026-05-13 | |||
| 2023-12-31 | $419.00K 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |